South Africa’s public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs that use a similar device for delivery.
Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month.
No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen.
Novo Nordisk’s drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens.
A month’s supply of Ozempic in the United States costs about $1,000, far more than insulin.
Persons:
”, Ambre James, Brown
Organizations:
Novo Nordisk
Locations:
South Africa, U.S, Ozempic, United States